Previous 10 | Next 10 |
Company reports first quarter 2020 XHANCE net revenue of $7.1 million First quarter 2020 XHANCE prescriptions increased 149% from first quarter 2019 Conference call and webcast to be held today at 4:15 p.m. Eastern Time YARDLEY, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Optinose ...
Conference Call and Webcast Scheduled for Thursday, May 7 at 4:15 p.m. Eastern Time YARDLEY, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced t...
At least 13 of the 200-plus public companies that received coronavirus hardship loans have said they would return the money after coming under fire for seeking aid meant for small business, WSJ reports, but others argue they have no other resources to keep paying workers. More news on:...
Following objections over large publicly traded companies getting forgivable loans under the Payroll Protection Program, the U.S. Treasury issues new guidance explaining that the program is meant for companies with little access to other sources of capital, not for publicly traded companie...
Even with the U.S. Senate set to vote later today on passing an additional relief bill for small businesses in the U.S., there is a bright spotlight being thrown on where the funds from the original Paycheck Protection Program designed for small business went. More news on: Legacy Housing ...
Quick Take Lyra Therapeutics ( LYRA ) has filed to raise $57.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is advancing a pipeline of treatment candidates for chronic rhinosinusitis patients. LYRA is in Phase 2 trials for its lead cand...
YARDLEY, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter and year-end 2019, before...
YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Victor M. Clavelli as Chief Commercial Officer. Mr. Clavelli joins Opti...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Allogene Therapeutics (NASDAQ: ALLO ) initiated with Market Perform rating and $37 (36% upside) price target at JMP Securities. More news on: Allogene Therapeutics, Inc., CorMedix, Inc., Fortress Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...
2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...